GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » abrdn Life Sciences Investors (NYSE:HQL) » Definitions » Return-on-Tangible-Equity

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Return-on-Tangible-Equity : -5.55% (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is abrdn Life Sciences Investors Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. abrdn Life Sciences Investors's annualized net income for the quarter that ended in Sep. 2023 was $-22.90 Mil. abrdn Life Sciences Investors's average shareholder tangible equity for the quarter that ended in Sep. 2023 was $412.29 Mil. Therefore, abrdn Life Sciences Investors's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 was -5.55%.

The historical rank and industry rank for abrdn Life Sciences Investors's Return-on-Tangible-Equity or its related term are showing as below:

HQL' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -22.71   Med: 6.09   Max: 28.38
Current: 5.49

During the past 7 years, abrdn Life Sciences Investors's highest Return-on-Tangible-Equity was 28.38%. The lowest was -22.71%. And the median was 6.09%.

HQL's Return-on-Tangible-Equity is ranked better than
52.72% of 1673 companies
in the Asset Management industry
Industry Median: 4.52 vs HQL: 5.49

abrdn Life Sciences Investors Return-on-Tangible-Equity Historical Data

The historical data trend for abrdn Life Sciences Investors's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

abrdn Life Sciences Investors Return-on-Tangible-Equity Chart

abrdn Life Sciences Investors Annual Data
Trend Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Return-on-Tangible-Equity
Get a 7-Day Free Trial -16.41 28.38 12.82 -22.71 5.59

abrdn Life Sciences Investors Semi-Annual Data
Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.86 -31.83 -13.59 16.48 -5.55

Competitive Comparison of abrdn Life Sciences Investors's Return-on-Tangible-Equity

For the Asset Management subindustry, abrdn Life Sciences Investors's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


abrdn Life Sciences Investors's Return-on-Tangible-Equity Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, abrdn Life Sciences Investors's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where abrdn Life Sciences Investors's Return-on-Tangible-Equity falls into.



abrdn Life Sciences Investors Return-on-Tangible-Equity Calculation

abrdn Life Sciences Investors's annualized Return-on-Tangible-Equity for the fiscal year that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Sep. 2023 )  (A: Sep. 2022 )(A: Sep. 2023 )
=22.352/( (397.902+401.934 )/ 2 )
=22.352/399.918
=5.59 %

abrdn Life Sciences Investors's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Mar. 2023 )(Q: Sep. 2023 )
=-22.902/( (422.646+401.934)/ 2 )
=-22.902/412.29
=-5.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Sep. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


abrdn Life Sciences Investors  (NYSE:HQL) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


abrdn Life Sciences Investors Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of abrdn Life Sciences Investors's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


abrdn Life Sciences Investors (abrdn Life Sciences Investors) Business Description

Traded in Other Exchanges
N/A
Address
1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing primarily in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have significant potential for above-average growth.
Executives
Todd Reit director C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Bill Maher director 600 WEST BROADWAY, 30TH FL., SAN DIEGO CA 92101
Rose Dimartino director C/O ABRDN, 1900 MARKET STREET, PHILADELPHIA PA 19103
James Joseph O'connor other: Director of Adviser C/O ABERDEEN STANDARD INVESTMENTS, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Marika Tooze other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Aberdeen Standard Investments Inc. other: Adviser 1900 MARKET ST., 2ND FLOOR, PHILADELPHIA PA 19103
Jaclyn Marie Matsick other: Director of Adviser C/O ABRDN, 1900 MARKET STREET, SUITE 200, PHILADELPHIA PA 19103
Lucia Sitar officer: VP and Chief Legal Officer 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Jennifer A Nichols other: Director of Adviser 1735 MARKET STREET, 37TH FLOOR, PHILADELPHIA PA 19103
Christian Pittard officer: President ONE BOW CHURCHYARD, LONDON X0 EC4M 9HH
Megan Kennedy officer: Secretary and Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Sharon Ferrari officer: Treasurer and CFO 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Alan R Goodson officer: Vice President 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Joseph Andolina officer: Chief Compliance Officer & VP 1735 MARKET STREET, 32ND FLOOR, PHILADELPHIA PA 19103
Stephen Bird director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10022

abrdn Life Sciences Investors (abrdn Life Sciences Investors) Headlines

From GuruFocus

Tekla Life Sciences Investors Declares Stock Distribution

By Business Wire Business Wire 05-18-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 02-16-2021

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 11-12-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 09-30-2021

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 12-31-2020

Tekla Life Sciences Investors Declares Distribution

By Business Wire Business Wire 08-16-2022

Tekla Life Sciences Investors Paid Distribution

By Business Wire 06-30-2023

Tekla Life Sciences Investors Paid Distribution

By Business Wire Business Wire 06-30-2021